drugset / Trial / NCT00673205

(Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate Cancer

NCT00673205

Phase 3 Completed 3588 enrolled AstraZeneca
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.

Timeline

Start
1995-09
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bicalutamide Other / unclassified 150 mg Oral

Indications